The luxury market may have cooled in China, but contemporary players are gaining ground with clever strategies aimed at ...

Minor consumer holidays don’t just appear out of nowhere. There’s a method to the madness—and it’s juicier than you’d think.

Saphyre, Inc., an industry award winning fintech company using patent-approved technology to solve pre-trade activities and post-trade issues, announces that Ninety One has joined its network of ...

"Seeing is believing," the founder of lab company Truvian told me. So I tried its tabletop blood testing device—which promises results in 30 minutes—for myself.

I want to thank the Red Bull family and hope we continue to be friends," Marquez said in December on Red Bull-owned ...

UBS upgraded Roche (RHHBY) to Buy from Neutral with a price target of CHF 338, up from CHF 300. The company offers sustainable growth with ...

Roche (RHHBY) announced that the Food and Drug Administration has approved a New Drug Application for an Evrysdi tablet for people living with ...

Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Newleos Therapeutics is making its debut with $93.5 million aimed at developing safer and more effective neuroscience ...

Helmed by Roche alums, Newleos Therapeutics is taking over four drugs dropped from the Swiss pharma’s pipeline in early 2024.

Backed by Goldman Sachs, Novo Nordisk’s parent company and others, Newleos Therapeutics debuted Thursday with $94 million and ...

Shares of RHHBY opened at $39.25 on Thursday. Roche has a 52-week low of $29.20 and a 52-week high of $42.43. The company has a 50-day simple moving average of $36.22 and a 200-day simple moving ...